Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled Trial

Annals of the Rheumatic Diseases

Volumn 73, Issue 4, 2014, Pages 654-661

  Hørslev Petersen, Kim ^a,b   Hetland, Merete Lund ^c,d   Junker, Peter ^e   Pødenphant, Jan ^d   Ellingsen, Torkell ^f   Ahlquist, Palle ^g   Lindegaard, Hanne ^e   Linauskas, Asta ^h   Schlemmer, Annette ^i,j   Dam, Mette Yde ^f   Hansen, Ib ^k   Horn, Hans Christian ^g   Ammitzbøll, Christian Gytz ⁱ   Jørgensen, Anette ⁱ   Krintel, Sophine B ^c   Raun, Johnny ^a,b   Johansen, Julia S ^l   Østergaard, Mikkel ^c,d   Stengaard Pedersen, Kristian ⁱ  

^a King Christian the Xth Hospital   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f SILKEBORG REGIONAL HOSPITAL   (Denmark)

^g LILLEBAELT HOSPITAL   (Denmark)

^h NORTH DENMARK REGIONAL HOSPITAL   (Denmark)

ⁱ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^j AALBORG UNIVERSITY HOSPITAL   (Denmark)

^k VIBORG HOSPITAL   (Denmark)

^l UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TRIAMCINOLONE;

ACUTE HEART INFARCTION; ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ATROPHY; BASAL CELL CARCINOMA; BLURRED VISION; BRONCHITIS; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL EFFECTIVENESS; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DRUG EFFICACY; EMPYEMA; EUROPEAN LEAGUE AGAINST RHEUMATISM; EUROPEAN QUALITY OF LIFE 5 DIMENSION; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INFECTIOUS ARTHRITIS; INTENTION TO TREAT ANALYSIS; KNEE OSTEOARTHRITIS; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OPERA STUDY; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; RHEUMATOID ARTHRITIS; SHORT FORM 12; SIMPLIFIED DISEASE ACTIVITY INDEX; TACHYCARDIA;

CORTICOSTEROIDS; DISEASE ACTIVITY; DMARDS (BIOLOGIC); DMARDS (SYNTHETIC); EARLY RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRA-ARTICULAR; MALE; METHOTREXATE; MIDDLE AGED; QUALITY OF LIFE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRIAMCINOLONE;

EID: 84895428992     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202735     Document Type: Article

References (39)

1. McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010;69:1898-906.
2. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
3. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
4. Hetland ML, Stengaard-Pedersen K, Junker P, et al., CIMESTRA study group. Radiographic progression and remission rates in early rheumatoid arthritis-MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 2010;69:1789-95.
5. Hetland ML, Stengaard-Pedersen K, Junker P, et al., CIMESTRA Study Group. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 2006;54:1401-9.
6. Hetland ML, Ejbjerg B, Hørslev-Petersen K, et al., CIMESTRA study group. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009;68:384-90.
7. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. (Pubitemid 43122183)
8. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93. (Pubitemid 32162981)
9. Klareskog L, Van Der Heijde D, De Jager JP, et al., TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81. (Pubitemid 38296553)
10. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
11. Van Der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74. (Pubitemid 43672919)
12. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
13. Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet 2009;374:430-2.
14. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;10:1252-5. (Pubitemid 39359299)
15. Aletaha D, Smolen JS. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol. 2007;4:663-75. (Pubitemid 47163601)
16. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;3:404-13.
17. Thorsen H, Hansen TM, McKenna SP, et al. Adaptation into Danish of the Stanford Health Assessment Questionnaire (HAQ) and the Rheumatoid Arthritis Quality of Life Scale (RAQoL). Scand J Rheumatol 2001;2:103-9. (Pubitemid 32250800)
18. Linde L, Sørensen J, Østergaard M, et al. What factors influence the health status of patients with rheumatoid arthritis measured by the SF-12v2 Health Survey and the Health Assessment Questionnaire? J Rheumatol 2009;10:2183-9.
19. Sørensen J, Linde L, Ostergaard M, et al. Quality-adjusted life expectancies in patients with rheumatoid arthritis-comparison of index scores from EQ-5D, 15D, and SF-6D. Value Health 2012;2:334-9.
20. Schefte DB, Hetland ML. An open-source, self-explanatory touch screen in routine care. Validity of filling in the Bath measures on Ankylosing Spondylitis Disease Activity Index, Function Index, the Health Assessment Questionnaire and Visual Analogue Scales in comparison with paper versions. Rheumatology (Oxford) 2010;1:99-104.
21. Zecca E, Barone G, Corsello M, et al. Reliability of two different bedside assays for C-reactive protein in newborn infants. Clin Chem Lab Med 2009;47:1081-4.
22. Hetland ML. DANBIO-powerful research database and electronic patient record. Rheumatology (Oxford) 2011;50:69-77.
23. Balogh Z, Ruzsonyi E. Triamcinolone hexacetonide versus betamethasone. A double-blind comparative study of the long-term effects of intraarticular steroids in patients with juvenile chronic arthritis. Scand J Rheumatol (Suppl) 1987;67:80-2.
24. Van Tuyl LH, Lems WF, Voskuyl AE, et al. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 2008;67:1574-7.
25. Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999;353:1568-73. (Pubitemid 29219206)
26. Leirisalo-Repo M, Kautiainen H, Laasonen L, et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis 2013;72:851-7.
27. De Jong PH, Hazes JM, Barendregt PJ, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis. 2013;72:72-8.
28. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9. (Pubitemid 38942816)
29. Verstappen SM, Jacobs JW, Van Der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9. (Pubitemid 350032650)
30. Van Der Kooij SM, Le Cessie S, Goekoop-Ruiterman YP, et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 2009;68:1153-8.
31. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012;56:329-39.
32. Bijlsma JW. Disease control with glucocorticoid therapy in rheumatoid arthritis. Rheumatology (Oxford) 2012;51(Suppl 4):iv9-13.
33. Furtado RN, Oliveira LM, Natour J. Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: a randomized controlled study. J Rheumatol 2005;32:1691-8. (Pubitemid 41324805)
34. Haugeberg G, Morton S, Emery P, et al. Effect of intraarticular corticosteroid injections and inflammation on periarticular and generalised bone loss in early rheumatoid arthritis. Ann Rheum Dis 2011;70:184-7.
35. Hetland ML, Østergaard M, Ejbjerg B, et al., CIMESTRA study group. Short- and long-term efficacy of intraarticular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP. Ann Rheum Dis 2012;71:851-6.
36. Soubrier M, Puéchal X, Sibilia J, et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) 2009;48:1429-34.
37. Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64-71.
38. Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72:844-50.
39. Ranzolin A, Brenol JC, Bredemeier M, et al. Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. Arthritis Rheum 2009;61:794-800.